These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33186336)

  • 1. Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
    Liebchen U; Dorn C; Kees M; Schiesser S; Hitzenbichler F; Kees F; Paal M
    Ther Drug Monit; 2020 Dec; 42(6):909-910. PubMed ID: 33186336
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
    Al-Shaer MH; Alghamdi WA; Peloquin C
    Ther Drug Monit; 2020 Dec; 42(6):910. PubMed ID: 33197165
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.
    D'Cunha R; Bach T; Young BA; Li P; Nalbant D; Zhang J; Winokur P; An G
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
    Heil EL; Nicolau DP; Farkas A; Roberts JA; Thom KA
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.
    Al-Shaer MH; Alghamdi WA; Graham E; Peloquin CA
    Ther Drug Monit; 2020 Feb; 42(1):129-132. PubMed ID: 31318843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.
    D'Cunha R; Bach T; Young BA; Li P; Nalbant D; Zhang J; Winokur P; An G
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
    Blevins AM; Lashinsky JN; McCammon C; Kollef M; Micek S; Juang P
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
    Peyko V; Smalley S; Cohen H
    J Pharm Pract; 2017 Apr; 30(2):209-213. PubMed ID: 26912532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit.
    de Araujo OR; da Silva DC; Diegues AR; Arkader R; Cabral EA; Afonso MR; Louzada ME; Albertoni Ade C
    Braz J Infect Dis; 2007 Apr; 11(2):277-80. PubMed ID: 17625777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum.
    Bjergum MW; Barreto EF; Scheetz MH; Rule AD; Jannetto PJ
    J Appl Lab Med; 2021 Sep; 6(5):1202-1212. PubMed ID: 34086904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem.
    Raveh D; Muallem-Zilcha E; Greenberg A; Wiener-Well Y; Schlesinger Y; Yinnon AM
    QJM; 2006 Jun; 99(6):397-406. PubMed ID: 16682440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
    Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
    Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
    Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Piperacillin-Tazobactam Increase the Risk of Nephrotoxicity when Used with Vancomycin: A Meta-Analysis of Observational Trials.
    Mellen CK; Ryba JE; Rindone JP
    Curr Drug Saf; 2017; 12(1):62-66. PubMed ID: 27784223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preanalytical Stability of Piperacillin, Tazobactam, Meropenem, and Ceftazidime in Plasma and Whole Blood Using Liquid Chromatography-Tandem Mass Spectrometry.
    Mortensen JS; Jensen BP; Zhang M; Doogue M
    Ther Drug Monit; 2019 Aug; 41(4):538-543. PubMed ID: 31306394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.